- Home
- WYY vs CMMB Comparison
WYY vs CMMB Comparison
Compare WYY & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYY
- CMMB
- Stock Information
- Founded
- WYY 1991
- CMMB 2004
- Country
- WYY United States
- CMMB Israel
- Employees
- WYY N/A
- CMMB N/A
- Industry
- WYY EDP Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- WYY Technology
- CMMB Health Care
- Exchange
- WYY Nasdaq
- CMMB Nasdaq
- Market Cap
- WYY 32.7M
- CMMB 27.0M
- IPO Year
- WYY 1998
- CMMB N/A
- Fundamental
- Price
- WYY $4.81
- CMMB $1.60
- Analyst Decision
- WYY Strong Buy
- CMMB Strong Buy
- Analyst Count
- WYY 1
- CMMB 3
- Target Price
- WYY $7.00
- CMMB $7.33
- AVG Volume (30 Days)
- WYY 77.0K
- CMMB 119.1K
- Earning Date
- WYY 11-13-2024
- CMMB 11-14-2024
- Dividend Yield
- WYY N/A
- CMMB N/A
- EPS Growth
- WYY N/A
- CMMB N/A
- EPS
- WYY N/A
- CMMB N/A
- Revenue
- WYY $133,124,648.00
- CMMB N/A
- Revenue This Year
- WYY $25.94
- CMMB N/A
- Revenue Next Year
- WYY $13.22
- CMMB N/A
- P/E Ratio
- WYY N/A
- CMMB N/A
- Revenue Growth
- WYY 31.67
- CMMB N/A
- 52 Week Low
- WYY $1.65
- CMMB $0.42
- 52 Week High
- WYY $5.31
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- WYY 67.67
- CMMB 52.53
- Support Level
- WYY $4.25
- CMMB $1.54
- Resistance Level
- WYY $5.31
- CMMB $1.73
- Average True Range (ATR)
- WYY 0.33
- CMMB 0.16
- MACD
- WYY 0.11
- CMMB 0.01
- Stochastic Oscillator
- WYY 70.98
- CMMB 45.45
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically the company generates a majority of its revenue from the United States and rest from Europe.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.